title: Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension.
abstract: OBJECTIVE
  To assess the efficacy and safety of rimexolone 1% ophthalmic suspension in controlling intraocular inflammation after cataract extraction.
  
  
  METHODS
  Twelve independent investigational centers in the United States
  
  
  METHODS
  This study comprised 197 patients who had cataract extraction. Postoperatively, patients were randomized to a 2 week regimen of rimexolone 1% ophthalmic suspension or a placebo. Efficacy was analyzed by monitoring total anterior chamber cells and flare, other parameters of inflammation, and treatment failures. Safety was evaluated by monitoring treatment-related adverse events and intraocular pressure (IOP).
  
  
  RESULTS
  Rimexolone 1% was clinically and statistically more effective in suppressing cell and flare than the placebo (P < .02). The overall discontinuation rate for treatment-related adverse events was 5.3% in the rimexolone group and 22.2% in the placebo group. There were no between-group differences in IOP.
  
  
  CONCLUSIONS
  Rimexolone 1% ophthalmic suspension was safe and significantly more effective than a placebo in controlling intraocular inflammation after cataract extraction when used four times daily and continued for 2 weeks.
authors.affiliation: Sinskey Eye Institute, Santa Monica, California 90411-0031, USA.
authors.forename: K K
authors.initials: KK
authors.lastname: Assil
authors.forename: G
authors.initials: G
authors.lastname: Massry
authors.forename: R
authors.initials: R
authors.lastname: Lehmann
authors.forename: K
authors.initials: K
authors.lastname: Fox
authors.forename: R
authors.initials: R
authors.lastname: Stewart
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D009877:Endophthalmitis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D018918:Phacoemulsification / Q000009:adverse effects*; D011245:Pregnadienes / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012449:Safety; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions; D011245:Pregnadienes; D013535:Suspensions; C013769:rimexolone